<DOC>
	<DOCNO>NCT01053819</DOCNO>
	<brief_summary>In psoriasis patient , thick psoriatic plaque obscure lesion , clinician rely heavily visual inspection recognize suspicious atypical pigment lesion . However , successful systemic treatment subsequent clearing psoriatic plaque may allow clinician good evaluate pigment lesion , thereby increase likelihood early identification treatment suspicious lesion nonmelanoma skin cancer malignant melanoma .</brief_summary>
	<brief_title>Can We Miss Pigmented Lesions Psoriasis Patients ?</brief_title>
	<detailed_description>No description desire .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . Diagnosis moderate severe plaque psoriasis identify BSA great equal 10 % Psoriasis Area Severity Index score great equal 12 2 . Age 19 year 3 . Fitzpatrick skin type I , II III 4 . Candidate systemic treatment opinion investigator 5 . Willingness undergo treatment Enbrel outline 6 . Negative pregnancy test ( urine serum Î²Human Chorionic Gonadotrophin ) first dose study drug woman ( except surgically sterile , least 5 year postmenopausal ) . 7 . Negative Tuberculosis skin test entry study negative screening xray inconclusive Purified Protein Derivative reading ( borderline , reactive nondiagnostic ) prior bacille CalmetteGuerin inoculate subject . 8 . Sexually active subject childbearing potential must agree use medically acceptable form contraception screen throughout study 9 . Subject designee must ability selfinject study medication care giver home administer subcutaneous injection 10 . Must able willing give write informed consent comply requirement study protocol must authorize release use protect health information 1 . Serum creatinine &gt; 3.0 mg/dL ( 265 micromoles/L ) 2 . Serum potassium &lt; 3.5 mmol/L &gt; 5.5 mmol/L 3 . Serum alanine aminotransferase Aspartate transaminase &gt; 3 time upper limit normal Lab 4 . Platelet count &lt; 100,000/mm3 5 . White blood cell count &lt; 3,000 cells/mm3 6 . Hemoglobin , hematocrit , red blood cell count outside 30 % upper low limit normal Lab 7 . Systemic therapy use ( e.g . phototherapy , methotrexate , cyclosporine , oral steroid , systemic biologics ) within previous 4 week 8 . Topical therapy use ( e.g . topical steroid , vitamin D derivative ) within previous 2 week 9 . Subject currently enrol another investigational device drug trial ( ) , subject receive investigational agent ( ) within 28 day baseline visit . 10 . Subjects know hypersensitivity Enbrel component know antibody etanercept 11 . Prior concurrent cyclophosphamide therapy 12 . Concurrent sulfasalazine therapy 13 . Known Human immunodeficiency viruspositive status know history immunosuppressing disease 14 . Active severe infection within 4 week screen visit , screen baseline visit 15 . Untreated Lyme disease 16 . Severe comorbidities ( diabetes mellitus require insulin , CHF severity , MI , CVA TIA within 3 month screen visit , unstable angina pectoris , uncontrolled hypertension ( sit systolic BP &lt; 80 mm Hg &gt; 160 diastolic BP &gt; 100 mm Hg ) , oxygendependent severe pulmonary disease , history cancer within 5 year [ resect cutaneous basal squamous cell carcinoma situ cervical cancer ] ) 17 . History TB TB exposure , chronic hepatitis B hepatitis C , SLE , history multiple sclerosis , transverse myelitis , optic neuritis epilepsy 18 . History recent alcohol substance abuse ( &lt; 1 year ) 19 . Pregnant lactating female 20 . Use live vaccine 90 day prior , study 21 . Any condition judge patient 's physician cause clinical trial detrimental patient 22 . History noncompliance therapy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>melanoma</keyword>
	<keyword>non-melanoma skin cancer</keyword>
	<keyword>etanercept</keyword>
	<keyword>Enbrel</keyword>
</DOC>